1
|
Wu BQ, Liu DY, Shen TC, Lai YR, Yu TL, Hsu HL, Lee HM, Liao WC, Hsia TC. Effects of Hyperbaric Oxygen Therapy on Long COVID: A Systematic Review. Life (Basel) 2024; 14:438. [PMID: 38672710 PMCID: PMC11051078 DOI: 10.3390/life14040438] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2024] [Revised: 03/18/2024] [Accepted: 03/23/2024] [Indexed: 04/28/2024] Open
Abstract
The coronavirus disease (COVID-19) pandemic has resulted in an increasing population that is experiencing a wide range of long-lasting symptoms after recovery from the acute infection. Long COVID refers to this specific condition and is associated with diverse symptoms, such as fatigue, myalgias, dyspnea, headache, cognitive impairment, neurodegenerative symptoms, anxiety, depression, and a sense of despair. The potential of hyperbaric oxygen therapy (HBOT) to improve chronic fatigue, cognitive impairments, and neurological disorders has been established; therefore, the use of HBOT to treat long COVID has also been studied. We conducted a literature search between 1 January 2019 and 30 October 2023, focusing on the clinical efficacy and utility of HBOT for treating long COVID and found ten clinical studies that fit the review topic, including one case report, five one-group pretest-posttest design studies, one safety report from a randomized controlled trial (RCT), and three complete reports of RCTs. Most studies found that HBOT can improve quality of life, fatigue, cognition, neuropsychiatric symptoms, and cardiopulmonary function. Although HBOT has shown some benefits for long COVID symptoms, further rigorous large-scale RCTs are required to establish precise indications, protocols, and post-treatment evaluations.
Collapse
Affiliation(s)
- Bing-Qi Wu
- Department of Education, China Medical University Hospital, Taichung 404, Taiwan (D.-Y.L.); (H.-L.H.)
| | - De-Yi Liu
- Department of Education, China Medical University Hospital, Taichung 404, Taiwan (D.-Y.L.); (H.-L.H.)
- School of Medicine, China Medical University, Taichung 404, Taiwan; (Y.-R.L.)
| | - Te-Chun Shen
- School of Medicine, China Medical University, Taichung 404, Taiwan; (Y.-R.L.)
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung 404, Taiwan
- Hyperbaric Oxygen Therapy Center, China Medical University Hospital, Taichung 404, Taiwan
- Division of Critical Care Medicine, Chu Shang Show Chwan Hospital, Nantou 557, Taiwan
| | - Yu-Ru Lai
- School of Medicine, China Medical University, Taichung 404, Taiwan; (Y.-R.L.)
| | - Tsai-Ling Yu
- School of Medicine, China Medical University, Taichung 404, Taiwan; (Y.-R.L.)
| | - Hsiang-Li Hsu
- Department of Education, China Medical University Hospital, Taichung 404, Taiwan (D.-Y.L.); (H.-L.H.)
- School of Medicine, China Medical University, Taichung 404, Taiwan; (Y.-R.L.)
| | - Hsiu-Ming Lee
- Department of Education, China Medical University Hospital, Taichung 404, Taiwan (D.-Y.L.); (H.-L.H.)
- School of Medicine, China Medical University, Taichung 404, Taiwan; (Y.-R.L.)
| | - Wei-Chih Liao
- School of Medicine, China Medical University, Taichung 404, Taiwan; (Y.-R.L.)
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung 404, Taiwan
- Hyperbaric Oxygen Therapy Center, China Medical University Hospital, Taichung 404, Taiwan
| | - Te-Chun Hsia
- School of Medicine, China Medical University, Taichung 404, Taiwan; (Y.-R.L.)
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung 404, Taiwan
- Hyperbaric Oxygen Therapy Center, China Medical University Hospital, Taichung 404, Taiwan
| |
Collapse
|
2
|
Katz AA, Wainwright S, Kelly MP, Albert P, Byrne R. Hyperbaric oxygen effectively addresses the pathophysiology of long COVID: clinical review. Front Med (Lausanne) 2024; 11:1354088. [PMID: 38449882 PMCID: PMC10916685 DOI: 10.3389/fmed.2024.1354088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2023] [Accepted: 01/31/2024] [Indexed: 03/08/2024] Open
Abstract
Background The World Health Organization defines long COVID as "the continuation or development of new symptoms 3 months after the initial SARS-CoV-2 infection, with these symptoms lasting for at least 2 months with no other explanation." Estimations of approximately 50 million individuals suffer from long COVID, reporting low health-related quality of life. Patients develop ongoing persistent symptoms that continue for more than 12 weeks that are not explained by another alternative diagnosis. To date, no current therapeutics are effective in treating the underlying pathophysiology of long COVID. Discussion A comprehensive literature search using PubMed and Google Scholar was conducted and all available articles from November 2021 to January 2024 containing keywords long covid and hyperbaric oxygen were reviewed. These published studies, including case series and randomized trials, demonstrate that utilizing Hyperbaric Oxygen Therapy (HBO) provided significant improvement in patients with long COVID. Conclusion A large cohort of patients suffer from long COVID or post-COVID-19 syndrome after recovery from their acute infection with no effective treatment options. HBO is a safe treatment and may provide benefit for this population and should continue to be researched for adjunctive treatment of long COVID.
Collapse
Affiliation(s)
- Alan A. Katz
- Hyperbaric Medical Solutions, New York, NY, United States
- Orlando College of Osteopathic Medicine, Winter Garden, FL, United States
| | - Sandra Wainwright
- Greenwich Hospital, Yale New Haven Health System, New Haven, CT, United States
| | - Matthew P. Kelly
- University of Alabama at Birmingham, Heersink School of Medicine, Birmingham, AL, United States
| | - Pradeep Albert
- Orlando College of Osteopathic Medicine, Winter Garden, FL, United States
| | - Rosemary Byrne
- Hyperbaric Medical Solutions, New York, NY, United States
| |
Collapse
|
3
|
Bustos-Viviescas BJ, Lozano Zapata RE, García Yerena CE. [Acid-base balance and long COVID: comments on metabolic-respiratory alterations]. REVISTA DE LA FACULTAD DE CIENCIAS MÉDICAS 2023; 80:568-573. [PMID: 38150196 PMCID: PMC10851397 DOI: 10.31053/1853.0605.v80.n4.42580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2023] [Accepted: 10/09/2023] [Indexed: 12/28/2023] Open
Abstract
Long COVID is a multi-organ pathology with important sequelae that affect the health and welfare of survivors from the cellular bioenergetics, in this case, the importance of considering the acid-base balance within the processes of evaluation and treatment of long COVID by health and sports professionals was addressed, given that different investigations have found important modifications in mitochondrial function that result in ventilation failures, causing alterations in the compensation-decompensation of respiratory and renal pH control (metabolic-respiratory acidosis and alkalosis).
Collapse
|
4
|
Mrakic-Sposta S, Vezzoli A, Garetto G, Paganini M, Camporesi E, Giacon TA, Dellanoce C, Agrimi J, Bosco G. Hyperbaric Oxygen Therapy Counters Oxidative Stress/Inflammation-Driven Symptoms in Long COVID-19 Patients: Preliminary Outcomes. Metabolites 2023; 13:1032. [PMID: 37887357 PMCID: PMC10608857 DOI: 10.3390/metabo13101032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2023] [Revised: 09/15/2023] [Accepted: 09/22/2023] [Indexed: 10/28/2023] Open
Abstract
Long COVID-19 patients show systemic inflammation and persistent symptoms such as fatigue and malaise, profoundly affecting their quality of life. Since improving oxygenation can oppose inflammation at multiple tissue levels, we hypothesized that hyperbaric oxygen therapy (HBOT) could arrest inflammation progression and thus relieve symptoms of COVID-19. We evaluated oxy-inflammation biomarkers in long COVID-19 subjects treated with HBOT and monitored with non-invasive methods. Five subjects (two athletes and three patients with other comorbidities) were assigned to receive HBOT: 100% inspired O2 at 2.4 ATA in a multiplace hyperbaric chamber for 90 min (three athletes: 15 HBOT × 5 days/wk for 3 weeks; two patients affected by Idiopathic Sudden Sensorineural Hearing Loss: 30 HBOT × 5 days/wk for 6 weeks; and one patient with osteomyelitis: 30 HBOT × 5 days/wk for week for 6 weeks and, after a 30-day break, followed by a second cycle of 20 HBOT). Using saliva and/or urine samples, reactive oxygen species (ROS), antioxidant capacity, cytokines, lipids peroxidation, DNA damage, and renal status were assessed at T1_pre (basal level) and at T2_pre (basal level after treatment), and the results showed attenuated ROS production, lipid peroxidation, DNA damage, NO metabolites, and inflammation biomarker levels, especially in the athletes post-treatment. Thus, HBOT may represent an alternative non-invasive method for treating long COVID-19-induced long-lasting manifestations of oxy-inflammation.
Collapse
Affiliation(s)
- Simona Mrakic-Sposta
- Institute of Clinical Physiology, National Research Council (IFC-CNR), 20162 Milan, Italy;
| | - Alessandra Vezzoli
- Institute of Clinical Physiology, National Research Council (IFC-CNR), 20162 Milan, Italy;
| | | | - Matteo Paganini
- Department of Biomedical Sciences, University of Padova, 35122 Padova, Italy; (M.P.); (E.C.); (T.A.G.); (J.A.); (G.B.)
| | - Enrico Camporesi
- Department of Biomedical Sciences, University of Padova, 35122 Padova, Italy; (M.P.); (E.C.); (T.A.G.); (J.A.); (G.B.)
| | - Tommaso Antonio Giacon
- Department of Biomedical Sciences, University of Padova, 35122 Padova, Italy; (M.P.); (E.C.); (T.A.G.); (J.A.); (G.B.)
| | - Cinzia Dellanoce
- Institute of Clinical Physiology, National Research Council (IFC-CNR), 20162 Milan, Italy;
| | - Jacopo Agrimi
- Department of Biomedical Sciences, University of Padova, 35122 Padova, Italy; (M.P.); (E.C.); (T.A.G.); (J.A.); (G.B.)
| | - Gerardo Bosco
- Department of Biomedical Sciences, University of Padova, 35122 Padova, Italy; (M.P.); (E.C.); (T.A.G.); (J.A.); (G.B.)
| |
Collapse
|
5
|
Chen J, Huang F, Fu J, Zhao J, Li J, Peng Z, Zhao J, Xu B, Li S, Zhang Q, Liang S, Li Y. Hyperbaric oxygen therapy: a possible choice for patients with resistant thin endometrium during frozen embryo transfer treatments. Reprod Biol Endocrinol 2023; 21:80. [PMID: 37658414 PMCID: PMC10472734 DOI: 10.1186/s12958-023-01123-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/11/2023] [Accepted: 07/26/2023] [Indexed: 09/03/2023] Open
Abstract
BACKGROUND Thin endometrium is considered suboptimal for embryo implantation, leading to compromised pregnancy rates without effective therapies. While some studies have reported promoted endometrial growth after a period of hyperbaric oxygen therapy (HBOT) in patients with intrauterine adhesion, there have been no reports in patients with resistant thin endometrium. The purpose of this study was to investigate the impact of HBOT on endometrium growth and pregnancy outcomes in patients with resistant thin endometrium during frozen embryo transfer (FET) treatments. METHODS This prospective pre-post cohort study was conducted at a university-affiliated assisted reproductive medical center between October 2021 and December 2022. Patients who had experienced at least one canceled transfer cycle due to a thin endometrium(< 7 mm) on the endometrium transformation day, despite the use of standard therapies as well as adjuvant therapies, were enrolled in the study. Patients were assigned voluntarily to either the HBOT group or the concurrent control group. The HBOT group received daily HBOT for at least 10 days during the proliferative phase, in addition to the routine endometrium preparation methods and the concurrent control group underwent cycles without HBOT. Propensity score matching (PSM) was used to ensure comparability between the groups. Both self-control and case-control comparisons were conducted. The primary outcome measured was endometrial thickness (ET) on the day of endometrium transformation. Secondary outcomes included intrauterine pregnancy rate (IPR), embryo implantation rate (IR), miscarriage rate, and others. RESULTS Patients in the HBOT group demonstrated a significantly thicker endometrial thickness on the day of endometrium transformation after undergoing therapy (5.76 ± 1.66 vs. 6.57 ± 1.23, P = 0.002). This improvement was accompanied by a decreased rate of cycle cancellations. Baseline parameters and endometrial thickness were comparable between the HBOT group and the concurrent control group during the cycle. The IPR was similar in patients who received cleavage-stage embryos (0.0% vs. 6.7%, P = 1.00), but significantly higher in patients in the HBOT group who received blastocysts (53.8% vs. 18.2%, P = 0.017). CONCLUSIONS A period of HBOT prior to endometrium transformation contributes to increased endometrial thickness and facilitates blastocyst implantation in patients with resistant thin endometrium during FET treatments. TRIAL REGISTRATION The trial was registered on the Chinese Clinical Trial Registry (registration no. ChiCTR2300072831, retrospectively registered).
Collapse
Affiliation(s)
- Jingjing Chen
- Department of Reproductive Medicine, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan Province, 410008, China
- Clinical Research Center for Women's Reproductive Health in Hunan Province, Changsha, Hunan Province, 410008, China
| | - Fangling Huang
- Department of Hyperbaric Oxygen, Xiangya Hospital, Central South University, Changsha, Hunan Province, 410008, China
| | - Jing Fu
- Department of Reproductive Medicine, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan Province, 410008, China
- Clinical Research Center for Women's Reproductive Health in Hunan Province, Changsha, Hunan Province, 410008, China
| | - Jianjuan Zhao
- STI-Zhilian Research Institute for Innovation and Digital Health, #1203, Building 1, No. 21, 18 Fuxing Road, Haidian District, Beijing, 410000, China
| | - Jinsheng Li
- Department of Hyperbaric Oxygen, The First Affiliated Hospital, Southern University of Science and Technology, Shenzhen, 518071, China
| | - Zhengrong Peng
- Department of Hyperbaric Oxygen, Xiangya Hospital, Central South University, Changsha, Hunan Province, 410008, China
| | - Jing Zhao
- Department of Reproductive Medicine, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan Province, 410008, China
- Clinical Research Center for Women's Reproductive Health in Hunan Province, Changsha, Hunan Province, 410008, China
| | - Bin Xu
- Department of Reproductive Medicine, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan Province, 410008, China
- Clinical Research Center for Women's Reproductive Health in Hunan Province, Changsha, Hunan Province, 410008, China
| | - Shuyi Li
- Department of Reproductive Medicine, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan Province, 410008, China
- Clinical Research Center for Women's Reproductive Health in Hunan Province, Changsha, Hunan Province, 410008, China
| | - Qiong Zhang
- Department of Reproductive Medicine, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan Province, 410008, China.
- Clinical Research Center for Women's Reproductive Health in Hunan Province, Changsha, Hunan Province, 410008, China.
| | - Shaolin Liang
- STI-Zhilian Research Institute for Innovation and Digital Health, #1203, Building 1, No. 21, 18 Fuxing Road, Haidian District, Beijing, 410000, China.
- Institute for Six-sector Economy, Fudan University, Shanghai, 200433, China.
- Xiangya Hospital, "Mobile Health" Ministry of Education-China Mobile Joint Laboratory, Central South University, Changsha, Hunan Province, 410008, China.
| | - Yanping Li
- Department of Reproductive Medicine, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan Province, 410008, China.
- Clinical Research Center for Women's Reproductive Health in Hunan Province, Changsha, Hunan Province, 410008, China.
| |
Collapse
|
6
|
Sardu C, Marfella R. COVID-19 and Its Cardiovascular Effects: Risk Factors, Prevention and Management. J Clin Med 2023; 12:4457. [PMID: 37445492 DOI: 10.3390/jcm12134457] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2023] [Revised: 06/16/2023] [Accepted: 06/19/2023] [Indexed: 07/15/2023] Open
Abstract
Coronavirus disease 2019 (COVID-19) is caused by a positive-stranded, single-stranded RNA virus, which is a member of the Sarbecovirus subgenus (beta-CoV lineage B) [...].
Collapse
Affiliation(s)
- Celestino Sardu
- Department of Advanced Medical and Surgical Sciences, University of Campania, "Luigi Vanvitelli", 80126 Naples, Italy
| | - Raffele Marfella
- Department of Advanced Medical and Surgical Sciences, University of Campania, "Luigi Vanvitelli", 80126 Naples, Italy
| |
Collapse
|
7
|
Hyperbaric Oxygen Therapy in Plastic, Aesthetic, and Reconstructive Surgery: Systematic Review. SURGICAL TECHNIQUES DEVELOPMENT 2023. [DOI: 10.3390/std12010003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
Introduction: Hyperbaric oxygen therapy (HBOT) has been used over the past six decades to treat multiple conditions. This systematic review aims to identify and evaluate the clinical outcomes of hyperbaric oxygen therapy in the field of plastic, reconstructive, and aesthetic surgery, found in the literature from the year 2000 to the present. Methods: A systematic review of the literature focused on the conceptual and methodological aspects of the PRISMA Declaration. The search for clinical trials focused on the results of hyperbaric therapy in plastic, reconstructive, and cosmetic surgery. The Newcastle–Ottawa scale suggested by the Cochrane manual was applied to each study. The study was carried out with a defined protocol and was registered in PROSPERO, with code CRD42022301261. Results: From the 170 articles identified, 6 were selected. Five of them showed that hyperbaric oxygen therapy favored the reduction of the size of skin ulcers and increased the formation of granulation tissue (two trials; p < 0.05), increased the partial pressure of transcutaneous oxygen in patients with free flaps (one trial; p < 0.001), reduced perfusion in keloid scarring disorder (one trial; p < 0.01), and accelerated both the fading of melanin pigmentation and the decrease in age spot size (one trial; p < 0.05). The methodological quality was moderate in all cases because there was no blinding method reported. One study failed to find differences in flap survival, time to resolution of venous congestion, resolution of edema, and postoperative recovery period (p > 0.05). Conclusions: Hyperbaric oxygen therapy has been increasingly used in the field of plastic and reconstructive surgery, and has shown potential benefits in promoting wound healing, reducing the risk of infection, and improving the survival of tissues used in reconstructive procedures. Further research with more rigorous clinical trials is needed to fully understand the efficacy and optimal use of this therapy in the field of plastic and reconstructive surgery.
Collapse
|